Literature DB >> 18627654

Clostridium difficile infection: emerging concepts and treatments.

Thomas Mathew1, Philip A Higginbottom.   

Abstract

Clostridium difficile infection has become one of the most common causes of diarrhea in patients frequenting hospitals, skilled nursing facilities, and physicians' offices. Although the pathogenesis and clinical description were well elucidated three decades ago, cure during the initial episode now occurs in fewer than two thirds of patients exhibiting clinical illness. The past decade has brought a new strain with more toxin. Frequent relapses in elderly patients are now the norm rather than a rarity. This review is intended to update clinicians regarding diagnosis, infection control, and treatment, including treatment of the difficult-to-treat patient with multiple relapses of C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627654     DOI: 10.1007/s11894-008-0076-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  44 in total

1.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.

Authors:  Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

2.  Prognosis in Clostridium difficile infection complicating inflammatory bowel disease.

Authors:  Christian D Stone
Journal:  Gut       Date:  2008-02       Impact factor: 23.059

3.  Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.

Authors:  Arnoldo J Riquelme; Mario A Calvo; Ana M Guzmán; María S Depix; Patricia García; Carlos Pérez; Marco Arrese; Jaime A Labarca
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

4.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

5.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Recurrent infection with epidemic Clostridium difficile in a peripartum woman whose infant was asymptomatically colonized with the same strain.

Authors:  Michelle T Hecker; Michelle M Riggs; Claudia K Hoyen; Christina Lancioni; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

7.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

8.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors:  David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Clostridium difficile skin contamination in patients with C. difficile-associated disease.

Authors:  Greg S Bobulsky; Wafa N Al-Nassir; Michelle M Riggs; Ajay K Sethi; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.